Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Incidence of type 2 diabetes mellitus and hyperlipidemia in patients prescribed dasatinib or nilotinib as first- or second-line therapy for chronic myelogenous leukemia in the US
Meg Franklin, Leah Burns, Samuel Perez, et al.
Current Medical Research and Opinion (2017) Vol. 34, Iss. 2, pp. 353-360
Closed Access | Times Cited: 30

Showing 1-25 of 30 citing articles:

Adverse reactions after treatment with dasatinib in chronic myeloid leukemia: Characteristics, potential mechanisms, and clinical management strategies
Fang Cheng, Qiling Xu, Qiang Li, et al.
Frontiers in Oncology (2023) Vol. 13
Open Access | Times Cited: 12
THERAPY OF ENDOCRINE DISEASE: Endocrine-metabolic effects of treatment with multikinase inhibitors
Poupak Fallahi, Silvia Martina Ferrari, Giusy Elia, et al.
European Journal of Endocrinology (2020) Vol. 184, Iss. 1, pp. R29-R40
Open Access | Times Cited: 29
How to manage CML patients with comorbidities
Jorge E. Cortés
Blood (2020) Vol. 136, Iss. 22, pp. 2507-2512
Closed Access | Times Cited: 28
BCR-ABL Tyrosine Kinase Inhibitors: Which Mechanism(s) May Explain the Risk of Thrombosis?
Hélène Haguet, Jonathan Douxfils, C Chatelain, et al.
TH Open (2018) Vol. 02, Iss. 01, pp. e68-e88
Open Access | Times Cited: 26
Expert opinion on the metabolic complications of new anticancer therapies: Tyrosine kinase inhibitors
P. Buffier, Benjamin Bouillet, Sarra Smati, et al.
Annales d Endocrinologie (2018) Vol. 79, Iss. 5, pp. 574-582
Closed Access | Times Cited: 26
A practical guide to managing hypertension, hyperlipidemia, and hyperglycemia in patients with chronic myeloid leukemia
Khalid Ahmed, Rasha Kaddoura, Mohamed A. Yassin
Frontiers in Medicine (2022) Vol. 9
Open Access | Times Cited: 13
How to manage CML patients with comorbidities
Jorge E. Cortés
Hematology (2020) Vol. 2020, Iss. 1, pp. 237-242
Open Access | Times Cited: 18
New onset of type 2 diabetes as a complication after cancer diagnosis: A systematic review
Ara Jo, Lisa Scarton, LaToya J. O’Neal, et al.
Cancer Medicine (2020) Vol. 10, Iss. 2, pp. 439-446
Open Access | Times Cited: 18
Differential vascular endothelial cell toxicity of established and novel BCR-ABL tyrosine kinase inhibitors
Yihua Wang, Richard Travers, Alanna Farrell, et al.
PLoS ONE (2023) Vol. 18, Iss. 11, pp. e0294438-e0294438
Open Access | Times Cited: 6
Lifelong TKI therapy: how to manage cardiovascular and other risks
Michael J. Mauro
Hematology (2021) Vol. 2021, Iss. 1, pp. 113-121
Open Access | Times Cited: 11
Nilotinib-induced Diabetes in Japanese Patients with Chronic Myeloid Leukemia
Yuichiro Iwamoto, Tomohiko Kimura, Hideyuki Iwamoto, et al.
Internal Medicine (2024)
Open Access | Times Cited: 1
Cardiovascular Disease With Hormone Therapy and Ovarian Suppression in Premenopausal Breast Cancer Survivors
Elizabeth J. Polter, Anna E. Prizment, Rob F. Walker, et al.
JACC CardioOncology (2024) Vol. 6, Iss. 6, pp. 907-918
Open Access | Times Cited: 1
Tyrosine Kinase Targeting
Mohammad Althubiti
Saudi Journal of Medicine and Medical Sciences (2022) Vol. 10, Iss. 3, pp. 183-191
Open Access | Times Cited: 7
Metformin enhances the cytotoxic effect of nilotinib and overcomes nilotinib resistance in chronic myeloid leukemia cells
Yoo Jin Na, Eun Sang Yu, Dae Sik Kim, et al.
The Korean Journal of Internal Medicine (2020) Vol. 36, Iss. Suppl 1, pp. S196-S206
Open Access | Times Cited: 10
Tyrosine Kinase Inhibitors and Vascular Adverse Events in Patients with Chronic Myeloid Leukemia: A Population-Based, Propensity Score-Matched Cohort Study
Mei-Tsen Chen, Shih‐Tsung Huang, Chih‐Wan Lin, et al.
The Oncologist (2021) Vol. 26, Iss. 11, pp. 974-982
Open Access | Times Cited: 9
Low‐Density Lipoproteins, High‐Density Lipoproteins (HDL), and HDL‐Associated Proteins Differentially Modulate Chronic Myelogenous Leukemia Cell Viability
Catherine J. Andersen, Lydia Dupree, Kristina Murray, et al.
Lipids (2020) Vol. 55, Iss. 6, pp. 615-626
Closed Access | Times Cited: 9
Cardiovascular events and atherogenic lipid profile in chronic myeloid leukemia patients treated with nilotinib versus imatinib
Lucia Petríková, Katarína Slezáková, Zuzana Sninská, et al.
Bratislavské lekárske listy/Bratislava medical journal (2021) Vol. 122, Iss. 08, pp. 531-537
Open Access | Times Cited: 8
Single frequency impedance strategy employed in rapid detection of leukemia cancer cells using an electrospun PES-nanofiber reinforced ternary composite-based cytosensor
Mojtaba Shamsipur, Mohammad Bagher Gholivand, Hosna Ehzari, et al.
Electrochimica Acta (2018) Vol. 283, pp. 1498-1506
Closed Access | Times Cited: 7
Association of Nilotinib With Cardiovascular Diseases in Patients With Chronic Myelogenous Leukemia: A National PopulationBased Cohort Study
Cih‐En Huang, Kuan‐Der Lee, Jung-Jung Chang, et al.
The Oncologist (2023) Vol. 29, Iss. 1, pp. e81-e89
Open Access | Times Cited: 2
Cardiovascular Events throughout the Disease Course in Chronic Myeloid Leukaemia Patients Treated with Tyrosine Kinase Inhibitors—A Single-Centre Retrospective Study
Andreea Varga, Ioan Ţilea, Dorina Nastasia Petra, et al.
Journal of Clinical Medicine (2020) Vol. 9, Iss. 10, pp. 3269-3269
Open Access | Times Cited: 5
Analysis on influencing factors of abnormal renal function in elderly patients with type 2 diabetes mellitus
Tao Chai, Dawei Zhang, Zhongxin Li
Minerva Endocrinologica (2020) Vol. 45, Iss. 1
Closed Access | Times Cited: 4
NOVEL-1st: an observational study to assess the safety and efficacy of nilotinib in newly diagnosed patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase in Taiwan
Wen‐Li Hwang, Tsung‐Chih Chen, Hsuan‐Yu Lin, et al.
International Journal of Hematology (2022) Vol. 115, Iss. 5, pp. 704-712
Closed Access | Times Cited: 3
Endothelium as a Source of Cardiovascular Toxicity From Antitumor Kinase Inhibitors
Richard Travers, Alec Stepanian, Iris Z. Jaffe
Arteriosclerosis Thrombosis and Vascular Biology (2024) Vol. 44, Iss. 10, pp. 2143-2153
Closed Access
Black Truffle Extract Exerts Antidiabetic Effects through Inhibition of Inflammation and Lipid Metabolism Regulation
Ziyuan Wu, Muthukumaran Jayachandran, Wai San Cheang, et al.
Oxidative Medicine and Cellular Longevity (2022) Vol. 2022, pp. 1-10
Open Access | Times Cited: 2
Future treatment of Diabetes – Tyrosine Kinase inhibitors
Aakash Kumar S, Snehal S. Patel, Shreya Patel, et al.
Journal of Diabetes & Metabolic Disorders (2022) Vol. 22, Iss. 1, pp. 61-71
Open Access | Times Cited: 2
Page 1 - Next Page

Scroll to top